P080 Bimekizumab efficacy and impact on pain in moderate-to-severe hidradenitis suppurativa: results from BE HEARD I and II
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Dermatology"
DOI: 10.1093/bjd/ljae090.107
Abstract: Hidradenitis suppurativa (HS) is a debilitating skin disease, with pain being the most impactful symptom. Treatment options are limited; bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, was studied… read more here.
Keywords: q2w; bkz; week; q4w ... See more keywords